Morgan Stanley Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price

BridgeBio Pharma (NASDAQ:BBIO) had its target price upped by Morgan Stanley from $96.00 to $98.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other equities research analysts have also weighed in on BBIO. HC Wainwright lifted their price objective on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. The Goldman Sachs Group lifted their price target on shares of BridgeBio Pharma from $55.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Sanford C. Bernstein started coverage on BridgeBio Pharma in a research note on Thursday, December 11th. They issued an “outperform” rating and a $94.00 price objective on the stock. TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, January 12th. Finally, Cantor Fitzgerald upped their target price on BridgeBio Pharma from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Twenty-two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BridgeBio Pharma presently has an average rating of “Moderate Buy” and an average price target of $82.50.

BridgeBio Pharma Stock Down 2.6%

BBIO opened at $66.54 on Wednesday. The business has a fifty day moving average of $75.09 and a 200 day moving average of $64.54. The stock has a market cap of $12.82 billion, a P/E ratio of -17.60 and a beta of 1.13. BridgeBio Pharma has a 52-week low of $28.33 and a 52-week high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The firm had revenue of $154.18 million during the quarter, compared to analyst estimates of $150.71 million. The company’s revenue was up 2521.2% on a year-over-year basis. During the same period last year, the business posted ($1.40) EPS. Equities analysts anticipate that BridgeBio Pharma will post -3.67 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total value of $754,600.00. Following the transaction, the director directly owned 11,589 shares in the company, valued at approximately $874,505.94. This trade represents a 46.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas Trimarchi sold 13,600 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total value of $1,016,192.00. Following the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at $25,149,631.20. This trade represents a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 204,174 shares of company stock worth $15,012,335 over the last quarter. Insiders own 18.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Corient Private Wealth LLC acquired a new position in shares of BridgeBio Pharma during the second quarter valued at about $643,000. WINTON GROUP Ltd acquired a new stake in BridgeBio Pharma in the 2nd quarter worth approximately $3,856,000. Principal Financial Group Inc. grew its position in BridgeBio Pharma by 23.0% during the 3rd quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock worth $65,829,000 after purchasing an additional 236,885 shares during the last quarter. Federated Hermes Inc. increased its stake in BridgeBio Pharma by 53.0% during the 3rd quarter. Federated Hermes Inc. now owns 424,695 shares of the company’s stock valued at $22,059,000 after purchasing an additional 147,108 shares in the last quarter. Finally, L & S Advisors Inc purchased a new position in shares of BridgeBio Pharma in the third quarter worth $877,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Q4 revenue beat and commercial update — BridgeBio reported $154.2M in Q4 revenue (well above estimates) and provided commercial progress on Attruby, which supports the company’s path to commercialization and helped lift sentiment. BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
• Positive Sentiment: Multiple analyst price-target increases — Morgan Stanley, Truist and other firms raised targets (Morgan Stanley to $98, Truist to $95 and others higher), signaling continued analyst confidence and providing upside thesis for longer-term holders. Analyst Coverage
• Neutral Sentiment: Conference call / transcripts available — The full earnings call and transcripts are published for investors to parse forward guidance and commercial cadence; further detail could move the stock once digested. Listen to Conference Call
• Neutral Sentiment: Short-interest report appears irregular — the February short-interest entry shows 0 shares / NaN change, likely a reporting glitch; this makes short-interest an unreliable read today. (No reliable source link provided in the alert.)
• Negative Sentiment: EPS missed expectations — BridgeBio reported a $1.00 loss per share vs. the consensus -$0.75, a larger-than-expected loss that is pressuring the stock despite the revenue beat. Zacks: Q4 Loss, Beats Revenue Estimates
• Negative Sentiment: Insider selling by CEO — CEO Neil Kumar sold ~28k shares (part of a pattern of recent sales), which can be interpreted negatively by some investors as liquidity-taking by management. InsiderTrades: Neil Kumar Sells Shares
• Negative Sentiment: One analyst trimmed target slightly — Oppenheimer lowered its target to $81 (still an outperform), introducing a modest counterpoint to the otherwise bullish analyst activity. Benzinga: Oppenheimer Price Target Change

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.